AFS

- 1 5

- 125

- E January 2 3 , 2015

Exemption No. 10690D Regulatory Docket No. FAA

- 2013

- 0034

Ms. Stacy Bechdolt, Esq. Director, Safety and Technical Affairs Regio nal Airline Association 2025 M Street NW, Suite 800 Washington, DC 20036

Mr. Robert Ireland Managing Director, Engineering and Maintenance

Airlines for America 1301 Pennsylvania Avenue NW, Suite 1100 Washington, DC 20004

Mr. George Paul

Director of Tech nical Services

National Air Carrier Association 1000 Wilson Boulevard, Suite 1700 Arlington, VA 22209

Dear Ms. Bechdolt :

This letter is to inform you that we have g ranted your petition to extend and amend Exemption No. 10690, as amended . It explains th e basis for our decision , describes its effect, and lists

the conditions and limitations.

The Basis for Our Decision

By letter dated October 30, 2014 , you petitioned the Federal Aviation Administration (FAA) on behalf of Regional Airline Association (RAA)

, Airlines for America (A4A) , and National2

Air Carrier Association (NACA) for an extension to an amendment of Exemption No. 10690, as amended. Specifically, the petitioners requested the following:

1. Extension of Exemption 10690 pertaining to Atropine, tha t expires on January 31, 201 5

.

2. The extension should allow kits to remain in the field that are short of the substances until normally returned for refurbishment (“grandfathering”), regardless of recovery of market supplies. The intent is to continue ext ensions for some period after supplies

are restored to avoid a sudden need to refurbish kits off

- schedule, unreasonably straining supply capabilities.

3. Carriers may use their own effective means to communicate that kits already in the field are covered by the proposed extension despite the expiration date of January

201 5 that may be apparent.

4. The extension should stipulate that it must be readily apparent that kits not containing Atropine are in compliance with Extension 10690 “as revised or extended

, ” wi thout displaying the expiration date.

5. Deletion of the requirement to carry a copy of the e xemption on board the affected

aircraft.

Your current exemption from § 121.803(c)(3) and Appendix A of Title 14, Code of Federal Regulations (14 CFR) allows RAA, A 4A, and NACA relief from the requirement to include Atropine in an Emergency Medical Kit (EMK). A condition of that exemption includes a requirement to carry a copy of the exemption aboard the affected aircraft.

In your petition, you indicate that ther e has been no change in the conditions and reasons relative to public interest and safety that were the basis for granting the original exemption.

The FAA has determined that good cause exists for not publishing a summary of the petition

in the Federal Re gister because the requested extension and amendment to the exemption would not set a precedent, and any delay in acting on this petition would be detrimental to RAA, A4A, and NACA.

Our Decision

The FAA has determined that the justification for the issuan ce of Exemption No. 10690, as amended, remains valid with respect to the this exemption and is in the public interest. Therefore, under the authority provided by 49 U.S.C. §§ 106(f), 40113, and 44701, which the FAA Administrator has delegated to me, passe nger member airlines of Regional Airline Association, Airlines for America, and National Air Carrier Association , and all similarly situated air carriers, are granted an extension of its exemption from 14 CFR § 121.803(c) (3)3

and Appendix A of part 121, to the extent necessary to relieve its holders from the requirement to carry two single dose ampules of Atropine 5cc injectable, in required on

- board EMKs when, due to the nationwide shortage discussed herein, they are unable to procure these

items for the ki ts

. Should the supply of single dose ampules of Atropine 5 cc injectable become available, exemption holders should refurbish the kits with atropine at the next

scheduled refurbishment date.

With regard to the request to amend the c onditions and l imita tions, the FAA denies the petitioners ’ request to waive the requirement to maintain a copy of the most current exemption with the expiration date on board the affected aircraft, because doing so would not
be in the public interest

. This exemption is subje ct to the following conditions and

limitations :

Conditions and Limitations

1. This exemption applies to part 119 certificate holders authorized to conduct part 121 passenger carrying operations

.

2. A copy of this exemption must be carried on board each aircr aft operating with emergency medical kits that do not include Atropine as required by Appendix A of part 121.

3. As part of the requirement under §119.43(c) to keep each of its employees and other persons used in its operation informed of the provisions of t heir operations specifications that apply to that employee’s or person’s duties and responsibilities, the certificate holders must inform crewmembers that any emergency medical kits on board the aircraft may not contain Atropine.

4. This exemption may be use d for flights conducted outside of the United States

.

The Effect of Our Decision

Our decision extends the termination date of Exemption No. 10690, as amended, to January 31, 201 6

, unless sooner superseded or rescinded.

Sincerely,

/s/

John S. Duncan Director, Flight Standards Service